Healthcare
Back within reach of the 2021 peak, but funding different things
Biotech venture funding peaked near $42bn in 2021, fell through the 2022–23 funding winter as rate rises closed the IPO window, and recovered to about $38bn in 2025, a 28% gain on 2024.
Biopharma specifically raised $23.3bn in 2023 and $26bn in 2024, with a higher share going to clinically de-risked assets rather than pre-clinical platform bets.
Biotech Venture Funding
- 2025
- Reputable secondary
- 5
- 3
- 5 actual
This page can answer
Two series: global biotech venture funding, and biopharma-specific venture funding.
It cannot answer
- Stage or therapeutic-area breakdowns.
- Deal counts or median round sizes.
- Returns or exit outcomes.
Venture capital invested in biotech.
Global biotech venture funding
Global biotech VC
Venture capital invested in biotech, $ billions.
Global biotech VC
Rendering the interactive chart…
Expand data table
| Dimension | Series | Value | Value basis | Source |
|---|---|---|---|---|
| 2021 | $bn invested | 42 | Actual | McKinsey: Next-generation platform technologies are driving the biotech VC surge |
| 2024 | $bn invested | 29.7 | Actual | McKinsey: Next-generation platform technologies are driving the biotech VC surge |
| 2025 | $bn invested | 38 | Actual | McKinsey: Next-generation platform technologies are driving the biotech VC surge |
Venture capital raised by biopharma companies.
Biopharma-specific venture funding
Biopharma VC
Venture capital raised by biopharma companies, $ billions.
Biopharma VC
Rendering the interactive chart…
Expand data table
| Period | Series | Value | Value basis | Source |
|---|---|---|---|---|
| 2023 | $bn raised | 23.3 | Actual | BioPharma Dive: Biotech venture capital funding tracker |
| 2024 | $bn raised | 26 | Actual | BioPharma Dive: Biotech venture capital funding tracker |